Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 6/20 | 0.38 |
| ▸ | HTR1B | P28222 | 6/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789148 | 0.89 | ALDH1A1 (0.42) | MCHR1DRD2ALDH1A1DRD4DRD3 | |
| SCHEMBL6790012 | 0.86 | NPC1 (0.46) | MCHR1DRD2DRD4DRD3HTR1D | |
| SCHEMBL6789667 | 0.85 | MTNR1A (0.53) | MCHR1MTNR1ANAMPT | |
| SCHEMBL6795413 | 0.85 | MTNR1A (0.41) | MCHR1DRD2ALDH1A1DRD4DRD3 | |
| SCHEMBL6796741 | 0.84 | RORC (0.46) | MCHR1HTR1DMTNR1ANAMPT | |
| SCHEMBL6795436 | 0.83 | MTNR1A (0.42) | MCHR1DRD2DRD4DRD3HTR1D | |
| SCHEMBL6792744 | 0.83 | RORC (0.45) | MCHR1MTNR1ANAMPT | |
| SCHEMBL6802341 | 0.83 | MCHR1 (0.51) | MCHR1NAMPT | |
| SCHEMBL6792004 | 0.83 | JAK2 (0.42) | MCHR1DRD2DRD4DRD3MTNR1A | |
| SCHEMBL6790682 | 0.81 | DRD2 (0.41) | MCHR1DRD2DRD4DRD3MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767907-B2 | FOR THERAPY OF PSYCHIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2004-07-27 | — | — | US | disclosed |
| US-6743808-B1 | PSYCHOLOGICAL AND NEUROLOGIC DISORDERS; CENTRAL SEROTONERGIC 5-HT1A AND 5-HT2A RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | PERREGAARD JENS KRISTIAN (DK) | 2003-10-16 | — | — | US | disclosed |
| US-6218394-B1 | FOR THERAPY OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, SUCH AS GENERALISED ANXIETY DISORDER, PANIC DISORDER | H. LUNDBECK A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0765311-B1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | LUNDBECK & CO AS H (DK) | 2000-10-04 | — | — | EP | disclosed |
| EP-0765311-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033721-A1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | CNR1, TPH1, CNR2 | MCHR1 92/4885DRD2 7/4885CACNA1G 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.